Dublin, Ireland, March 22nd, 2011 – ICON plc, a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, today announced details of its participation at Partnerships in Clinical Trials, taking place from March 30 – April 1 in Phoenix, Arizona. ICON experts, including Alan Morgan, President, Clinical Research Services, will educate attendees on a range of topics, including operational strategies for profitability and growth, clinical trial feasibility and best practices for strategic partnerships. Attendees will also be able to meet ICON senior executives and learn more about ICON’s range of services by visiting the ICON booth (#801) in the exhibit hall.
Wednesday, March 30th, 16:20: Operational Long Term Strategies for Profitability and Growth in Global Clinical Trials Alan Morgan, along with Eli Lilly, Purdue Pharma, Takeda and Allergan, will review and discuss commonalities and differences in their long term operational strategies for profitability and growth in global clinical trials.
Thursday, March 31st, 13:30: Clinical Trial Feasibility – Roadmap to Achieving Value and Return on Investment Katherine Tranotti, Vice President Clinical Operations, ICON Clinical Research, will co-present with representatives from Vertex Pharmaceuticals and Eli Lilly on an internal and external approach to clinical trial feasibility.
Friday, April 1st, 11:00: Committing to Two Partners – A Look at the BMS Integrated Strategic Sourcing Initiative Bari Kowal, Vice President Strategic Programs, ICON Clinical Research, will discuss BMS’ integrated strategic sourcing model with Joan Millsaps, Director, Business Operations and Outsourcing Management, BMS and Cynthia Hauck, Associate Director, Outsourcing Management, BMS.
About ICON plc
ICON plc is a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries. The Company specialises in the strategic development, management and analysis of programs that support clinical development - from compound selection to Phase I-IV clinical studies. ICON currently has around 7,100 employees, operating from 77 locations in 39 countries.
Further information is available at www.iconplc.com
Yasamin Omoomian Team Co-ordinator Weber Shandwick | Health Fox Court 14 Gray’s Inn Road London, WC1X 8WS
yomoomian@webershandwick.com www.webershandwick.co.uk
